Optimizing how to isolate extracellular vesicles from human follicular fluid
Official title: Optimization of the Isolation Protocol for Extracellular Vesicles (EVs) From Human Follicular Fluid
Run by University Hospital, Ghent · NCT06952751 · Data updated 2026-11-12
This study is testing different ways to separate tiny particles from human follicular fluid to see which method works best for understanding their role in egg development.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 4 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Status | Recruiting |
| Started | July 22, 2025 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT06952751 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients scheduled for oocyte retrieval at Ghent University Hospital.
✕Probably not a fit
Patients with conditions such as endometriosis, adenomyosis, or polycystic ovary syndrome (PCOS) may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to determine the most effective method for isolating extracellular vesicles (EVs) from human follicular fluid, which are believed to play a significant role in oocyte development. The research will compare three commonly used techniques: differential ultracentrifugation, OptiPrep™ density gradient ultracentrifugation, and size-exclusion chromatography, along with combined techniques. By identifying the optimal isolation protocol, the study seeks to enhance future research on the diagnostic and therapeutic potential of EVs and their contents. This foundational work is crucial for advancing our understanding of reproductive biology and potential clinical applications.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for isolating EVs, enhancing research into their roles in fertility and potential therapeutic applications.
How similar studies have gone: While there are limited studies comparing EV isolation techniques in human follicular fluid, this approach is essential for establishing a foundation for future research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients planned for an oocyte retrieval at Ghent University Hospital. Exclusion Criteria: * Diagnosis of endometriosis/adenomyosis * Diagnosis of PCOS (Polycystic Ovary Syndrome) * Macroscopic blood contamination at oocyte retrieval
Where it's running
-
Ghent University Hospital
Ghent, Belgium Recruiting
Study contacts
- Study coordinator: Dominic Stoop, Prof. dr.
- Email: arg.studies@uzgent.be
- Phone: + 329 332 34 42
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How eating cloudberries or lingonberries affects tiny cell particles called extracellular vesicles
We will test whether eating cloudberries or lingonberries for seven days changes extracellular vesicles in healthy adults.
-
Blood extracellular vesicles as markers of lung involvement in LAM and TSC.
We will test whether blood extracellular vesicles can show lung involvement in adults with LAM or tuberous sclerosis complex.
-
Looking at tiny particles in cord blood of babies born before 28 weeks
The team will test whether extracellular vesicles in umbilical cord blood can help predict serious complications in babies born before 28 weeks of pregnancy.
-
Examining extracellular vesicles in patients receiving CAR-T cell therapy
This study is trying to find out if certain tiny particles in the blood can help predict how well CAR-T cell therapy will work and if it will cause side effects in people with tough blood cancers.
-
Early detection of pancreatic cancer using a blood test
This study is testing a new blood test to see if it can help find pancreatic cancer earlier in people who are at high risk or show signs of the disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.